CP
CVS icon

Castleview Partners’s CVS Health CVS Stock Holding History

Castleview Partners’s Portfolio CVS Stock Details CVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-470
Closed -$20.8K – 258
2024
Q4 		$20.8K Buy
470
+73
+18% +$4.09K 0.01% 465
2024
Q3 		$25K Buy
397
+3
+0.8% +$175 0.01% 413
2024
Q2 		$23.3K Sell
394
-381
-49% -$23.8K 0.01% 421
2024
Q1 		$61.8K Buy
775
+20
+3% +$1.53K 0.03% 325
2023
Q4 		$59.6K Buy
755
+587
+349% +$41.8K 0.04% 274
2023
Q3 		$11.7K Sell
168
-253
-60% -$17.9K 0.01% 410
2023
Q2 		$29.1K Buy
421
+102
+32% +$7.26K 0.03% 324
2023
Q1 		$23.7K Buy
319
+1
+0.3% +$84 0.02% 323
2022
Q4 		$29.7K Buy
318
+221
+228% +$21.3K 0.03% 269
2022
Q3 		$9K Sell
97
-3
-3% -$297 0.01% 390
2022
Q2 		$2.58K Buy
100
+32
+47% +$3.12K ﹤0.01% 616
2022
Q1 		$6K Buy
+68
New +$7.14K ﹤0.01% 549
2021
Q2 		$31K Buy
+377
New +$30.9K 0.01% 488

Other funds holding CVS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Castleview Partners's CVS Position: Q1 2025 in Review

Castleview Partners sold out of CVS Health (CVS) in Q1 2025, closing a stake of 470 shares — an estimated $20.8K sold.

Castleview Partners first reported a position in CVS in Q2 2021 and held it in 13 quarters. The position peaked at $61.8K in Q1 2024. 1,756 funds tracked by Wall St. Rank hold CVS as of Q1 2025.

  • Castleview Partners reported no remaining CVS Health position as of Q1 2025 after selling out during the quarter.
  • Castleview Partners sold 470 CVS Health shares in Q1 2025, an estimated $20.8K.
  • Castleview Partners first reported a position in CVS Health in Q2 2021 and held it in 13 quarters.
  • Castleview Partners's CVS Health position peaked at $61.8K in Q1 2024.
  • 1,756 funds tracked by Wall St. Rank held CVS Health as of Q1 2025.

Based on Castleview Partners's 13F filing for Q1 2025, filed 22 Apr 2025.